Interleukin-6 level in serum and ascites as a prognostic factor in patients with epithelial ovarian cancer

Abstract

Background. Interleukin‐6 (IL‐6) is a multifunctional cytokine that can be produced by human ovarian cancer cells. Elevated IL‐6 levels have been found in the serum and ascites of patients with ovarian cancer, but its role in this disease has not been clearly established. Methods. The authors studied the relationship between IL‐6 levels in serum and ascites, various tumor parameters, and survival in 70 patients with newly diagnosed, untreated epithelial ovarian cancer. Ascites and serum specimens were obtained at the time of initial surgery, and IL‐6 levels were determined using the B9 bioassay. Results. All patients underwent platinum‐based chemotherapy after initial surgery. The median age of the group was 62 years (range, 28–87 years), and the median follow‐up time was 13 months (range, 12–59 months). Significantly higher IL‐6 levels were detected in patients' ascites (median, 49,612 pg/ml [range, < 1 to 680,330 pg/ml]) compared with serum (median, 10 pg/ml [range, < 1 to 1221 pg/ml]) (P < 0.0001). IL‐6 levels in ascites correlated significantly with the volume of ascites (P < 0.0001) and nearly so with the size of tumor found at initial surgery (P = 0.05). Serum and ascites IL‐6 levels did not correlate statistically with overall survival time, tumor stage, grade, histologic findings, residual tumor volume after debulking, and serum CA 125 levels. Although not statistically significant, patients who responded to chemotherapy tended to have lower ascites IL‐6 levels (median, 21,102 pg/ml) compared with patients who did not respond to chemotherapy (median, 40,200 pg/ml). Conclusions. IL‐6 is present in very high amounts in the ascites of patients with epithelial ovarian cancer. IL‐6 levels in ascites correlated significantly with ascites volume and initial tumor size. IL‐6 levels in ascites and serum did not correlate statistically with other tumor parameters or with survival time.

Discovery of a Novel Orally Active Small-Molecule gp130 Inhibitor for the Treatment of Ovarian Cancer

“…Inhibitory concentration 50% (IC 50 ) values were determined for each drug from a plot of log (drug concentration) versus percentage of cell growth inhibition. SDs were calculated on the basis of the IC 50 values obtained from at least 3 independent experiments.…”

Neuroendocrine influences on cancer biology

“…Clinically, individuals experiencing chronic stress have been shown to exhibit elevated circulating levels of IL-6 [51]. In ovarian cancer patients, elevated IL-6 is associated with poorer prognosis [52,53]. Lutgendorf and colleagues found that social support was associated with lower levels of IL-6 in the blood and ascites samples of ovarian cancer patients, thereby playing a protective role [54].…”

MicroRNA-106a regulates phosphatase and tensin homologue expression and promotes the proliferation and invasion of ovarian cancer cells

“…Among the cytokines reported to date, interleukin-6 (IL-6) is one of the pivotal immunoregulatory cytokines present in the ovarian cancer microenvironment; it induces several pathways leading to tumor proliferation, angiogenesis and chemoresistance (11). Higher serum and ascites levels of IL-6 have been found in patients with ovarian cancer than levels in patients with other malignancies, and levels have been shown to correlate with the extent of disease and poor clinical outcome (12)(13)(14). Tocilizumab is a humanized anti-human IL-6R antibody and binds to the IL-6-binding site of human IL-6R.…”